ARVN News and Press, Arvinas Inc. From 12/07/21

Shares of ARVN (ARVN +2.2%) are higher this morning after Cowen initiated the company with an outperform rating. The firm does not have a price target. Analyst Tyler Van Buren cites potential for ARV-471 and ARV-110. The former is in phase 2 for ER+/HER- breast cancer and the latter in phase ...

NEW HAVEN, Conn. and NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced today that updated safety and efficacy data from the Phase 1 dose escalation trial of ARV-471, a novel oral estrogen receptor (ER)-targeting PROteolysis TArget...

Arvinas was founded by Dr. Craig Crews, the pioneer in the field of targeted protein degradation. ARVN has a mega deal with Pfizer. It has a slew of catalysts in 2022 that should impact the stock positively. For further details see: Arvinas: 2022 Is Full Of Catalysts For...

NEW HAVEN, Conn., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Sean Cassidy, Chief Financial Officer, and Ian Taylor, Ph.D., Chief Scientific O...

Arvinas (NASDAQ:ARVN): Q3 GAAP EPS of -$0.94. Revenue of $9.28M (+22.1% Y/Y) Press Release For further details see: Arvinas reports Q3 results

NEW HAVEN, Conn., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the third quarter ended September 30, 2021 and provided a corpor...

Kymera is almost a pioneer in the targeted protein degradation space. What it lacks in the foundational pedigree it is trying to make up with prolific and diverse scientific work. The term foray makes this a non-zero-sum game. For further details see: Kymera: Targeting T...

SAN FRANCISCO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Neurona Therapeutics , a biotherapeutics company advancing restorative neural cell therapies for the treatment of chronic neurological disorders, today announced that it has appointed Brad Margus to its board of directors. Mr. Margus brin...

Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas Canada NewsWire HONG KONG , Aug. 9, 2021 /CNW/ -- Insilico Medicine is proud to announce...

Arvinas (NASDAQ:ARVN): Q2 GAAP EPS of -$1.03 misses by $0.17. Revenue of $5.54M (-3.7% Y/Y) beats by $0.09M. Shares -1.73% PM. Press Release For further details see: Arvinas EPS misses by $0.17, beats on revenue